Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Equities researchers at Desjardins dropped their FY2024 earnings estimates for Inovalis Real Estate Investment Trust in a research report issued to clients and investors on Monday, November 11th. Desjardins analyst A. Leon now forecasts that the company will post earnings of $0.01 per share for the year, down from their previous estimate of $0.06.
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The company had revenue of C$3.52 million for the quarter.
Inovalis Real Estate Investment Trust Price Performance
About Inovalis Real Estate Investment Trust
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Featured Stories
- Five stocks we like better than Inovalis Real Estate Investment Trust
- What Does a Stock Split Mean?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- About the Markup Calculator
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.
